▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

May 10, 2014 by Todd Campbell

3 Stocks Guaranteed Obamacare Profits

Obamacare's Medicaid expansion is driving sales higher at Molina Healthcare (MOH), United Healthcare (UNH), and Aetna (AET).

May 7, 2014 by Todd Campbell

Humana's Earnings: What You Need to Know

Humana (HUM) joined United Healthcare (UNH) and WellPoint (WLP) in reporting solid top-line growth, but costs tied to Obamacare weighed down profit in the quarter.

May 7, 2014 by Todd Campbell

3 Stocks Poised to Profit from This Medicaid Mess

More than 900,000 Californians await Medicaid approval, suggesting the state's private medicaid insurers Molina (MOH), Health Net (HNT), and Centene (CNC) may see sales and earnings climb.

May 7, 2014 by Todd Campbell

What Should Merck Do With Its $14 Billion Windfall?

Bayer (BAYRY) is handing over $14 billion in exchange for Merck's (MRK) consumer business. That gives Merck plenty of opportunity to reward shareholders, or make a big M&A splash.

May 6, 2014 by Todd Campbell

Einhorn Says Athenahealth May Crash 80%. Is He Right?

Here's what you need to know about David Einhorn's presentation at the Sohn Conference suggesting that athenahealth may tumble as much as 80%.

May 5, 2014 by Todd Campbell

3 Biotech Stocks Making Big Moves Last Week

Here are the reasons behind last week's big move in United Therapeutics (UTHR), Cubist Pharmaceuticals (CBST), and Incyte Corporation (INCY).

May 5, 2014 by Todd Campbell

Is Merrimack Pharmaceuticals Worth More Than $700 Million?

Merrimack Pharmaceuticals (MACK) reported solid results in late-stage pancreatic cancer trials causing shares to spike, but is there still room to run?

May 3, 2014 by Todd Campbell

Meet Lung Cancer's New Enemy

Novartis (NVS) won early approval for its lung cancer drug Zykadia, making it and Pfizer's (PFE) Xalkori the only ALK-inhibitors approved for treating ALK positive non-small-cell lung cancer.

May 3, 2014 by Todd Campbell

Why Tobacco Companies Should Hate Obamacare

Obamacare turns up the heat on health-care payers like Medicaid to cut costs, pitting private Medicaid insurers United Healthcare (UNH) and Aetna (AET) against tobacco heavyweights Altria (MO) and Reynold's (RAI).

May 2, 2014 by Todd Campbell

WellPoint's Big Surprise Isn't So Surprising

Thanks to lower health care costs and surging Medicaid enrollment, WellPoint (WLP) joined United Healthcare (UNH), and Aetna (AET) in reporting solid first-quarter results.

May 2, 2014 by Todd Campbell

Today's 3 Biotech Blow-Ups

Here's why Endocyte (ECYT), Merrimack Pharmaceuticals (MACK), and Pharmacyclics (PCYC) are falling sharply today.

Apr 30, 2014 by Todd Campbell

Would Merck Be the Best Buyer for AstraZeneca?

Pfizer (PFE) may be preparing to make a bid for AstraZeneca (AZN), but Merck & Co (MRK) would be a better suitor.

Apr 30, 2014 by Todd Campbell

Beyond Bristol's Big Dividend: 3 Things Investors Need to Know

Bristol-Myers (BMY) reported flat sales, but earnings and sales of its top selling drugs grew suggesting investors should look beyond the first quarter top line numbers.

Apr 30, 2014 by Todd Campbell

Earnings Round-up: Here's How Merck & Co Is Weathering Its Storm

New products and a strong balance sheet offer Merck (MRK) a chance to overcome headwinds and make shareholder-friendly decisions.

Apr 30, 2014 by Todd Campbell

Earnings Roundup: Is AbbVie on Borrowed Time?

AbbVie's (ABBV) posted solid first-quarter results, but that doesn't eliminate long-term risk tied to Humira's patent expiration.

Apr 29, 2014 by Todd Campbell

Earnings Roundup: Celgene's Rock-Solid Quarter Offers Opportunity

Here's what you need to know about Celgene's (CELG) first-quarter results and whether they support picking up shares during the current sell-off.

Apr 29, 2014 by Todd Campbell

Is AstraZeneca Really Worth $100 Billion?

Pfizer (PFE) hopes to acquire AstraZeneca (AZN) in a blockbuster deal that could propel it into the top five makers of diabetes medication worldwide.

Apr 28, 2014 by Todd Campbell

What You Need to Know About New Hepatitis C Drugs

New drugs from AbbVie (ABBV) and Bristol-Myers (BMY) may threaten Gilead's (GILD) and Johnson & Johnson's (JNJ) market share in hepatitis C treatment this year.

Apr 28, 2014 by Todd Campbell

Rite Aid Shouts "Me Too" and Jumps Into Retail Clinics

Rite Aid purchased RediClinic to enter the retail pharmacy clinic business dominated by competitors CVS and Walgreen.

Apr 27, 2014 by Todd Campbell

Can Marijuana Treat Diabetes?

Here's how U.K. based GW Pharmaceuticals (GWPH) hopes to treat diabetes using marijuana.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services